DEFINING CYTOKINES CONTENTS IN SOLVING MAIN CUNICAL ISSUES
Abstract
Breakthroughs in cytokine biology, appraisal of their importance in many diseases, and successes of anticytokine therapy have lead to an assumption that cytokines can be used as biomarkers in various clinical settings. The aim of this review is to discuss some data from the literature and our own data pertaining to the use of cytokines as biomarkers for the assessment of disease burden, prognosis, diagnosis, and prediction of response to treatment.
About the Authors
V. S. Shirinskiy
Research Institute of Clinical Immunology SB RAMS
Russian Federation
Russian Federation
I. V. Shirinskiy
Research Institute of Clinical Immunology SB RAMS
Russian Federation
Russian Federation
References
1. Хэгглин Р. Дифференциальная диагностика внутренних болезней. — М.: Инженер, 1993. — 794 с.
2. Ширинский И.В., Желтова О.И., Соловьева Н.Ю., Ширинский В.С. и др. Эффективность и безопасность симвастатина при ревматоидном артрите: открытое контролируемое исследование // Мед. иммунология. — 2007. — № 4 — 5. — С. 477 — 482.
3. Bauer D.C., Hunter D.J., Abramson S.B., Attur M. et al. Classification of osteoarthritis biomarkers: a proposed approach // Osteoarthritis Cartilage. — 2006. — Vol. 14. — P. 723 — 727.
4. Bozza F.A., Salluh J.I., Japiassu A.M., Soares M. et al. Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis // Crit Care. — 2007. — Vol. 11. — P. 49.
5. Danesh J., Kaptoge S., Mann A.G., Sarwar N. et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review // PLoS Med. — 2008. — Vol. 5. — P. 78.
6. Gattorno M., Federici S., Pelagatti M.A., Caorsi R. et al. Diagnosis and management of autoinflammatory diseases in childhood // J. Clin. Immunol. — 2008. — Vol. 28. — Suppl. 1. — P. 73 — 83.
7. Rho Y.H., Chung C.P., Oeser A., Solus J. et al. Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis // Arthritis Rheum. — 2009. — Vol. 61. — P. 1580—1585.
8. Rooney T., Roux-Lombard P., Veale D.J., FitzGerald O. et al. Synovial tissue and serum biomarkers of disease activity, therapeutic response and radiographic progression: analysis of a proof-of-concept randomised clinical trial of cytokine blockade // Ann. Rheum. Dis. — 2010. — Vol. 69. — P. 706 — 714.
9. Sahab Z.J., Semaan S.M., Sang Q.X. Methodology and applications of disease biomarker identification in human serum // Biomark Insights. — 2007. — Vol. 2. — P. 21—43.
10. Shirinsky I.V., Zheltova O.I., Solovyova N.Y., Kozlov V.A. et al. Changes in disease activity, cytokine production, and proliferation of peripheral blood mononuclear cells in patients with rheumatoid arthritis after simvastatin treatment // Scand. J. Rheumatol. — 2009. — Vol. 38. — P. 23 — 27.
11. Syversen S.W., Landewe R., van der Heijde D., Bathon J.M. et al. Testing of the OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage in rheumatoid arthritis: a systematic literature search on 5 candidate biomarkers // J. Rheumatol. — 2009. — Vol. 36. — P. 1769 — 1784.
12. Fletcher R.H., Fletcher S.W. Clinical Epidemiology. The Essentials, 4th ed. — Baltimore: Lipincott Williams and Wilkins, 2005. — 288 p.
Review
For citations:
Shirinskiy V.S., Shirinskiy I.V. DEFINING CYTOKINES CONTENTS IN SOLVING MAIN CUNICAL ISSUES. Acta Biomedica Scientifica. 2012;(3(2)):355-357. (In Russ.)
Views:
524
.png)
Email this article 
